您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Nullscript
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nullscript
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nullscript图片
CAS NO:300816-11-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt298.3
Cas No.300816-11-9
FormulaC16H14N2O4
Solubility≤2mg/ml in DMSO;2mg/ml in dimethyl formamide
Chemical NameN-hydroxy-1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-butanamide
Canonical SMILESO=C(C1=CC=CC2=CC=CC3=C12)N(CCCC(NO)=O)C3=O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Nullscript is an HDAC inhibitor.

Histone deacetylase inhibitors (HDIs) have been used in psychiatry and neurology as mood stabilizers and anti-epileptics, such as valproic acid. Recently, HDIs are being studied as a mitigator or treatment for neurodegenerative diseases. Moreover, there has been an effort to develop HDIs for cancer therapy.

In vitro: Nullscript, a close analog of scriptaid, was found to be inactive in transcriptional facilitation at corresponding concentrations, which confirmed a minimal requirement for the length of the linker chain expected for this class of HDAC inhibitors. In addition, nullscript was not able to induce the p6SBE-luc reporter construct, which was identified from the library using ChemFinder by its structural similarity to scriptaid [1].

In vivo: A standard in vivo model of cardiac I/RWe was utilized to examine the in vivo consequences of HDAC inhibition in the intact heart. Results showed that the treatment with scriptaid led to a nearly identical effect when compared to nullscript, with a 46.8% reduction in infarct size. Such results strongly suggested that in murine models, HDACIs could reverse the induction of ischemia-induced HDAC activity and reduced myocardial infarct size by more than 50% [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] G.  H. Su, T. A. Sohn, B. Ryu, et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Research 60, 3137-3142 (2000).
[2] Anne Granger et al.  Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 2008 Oct; 22(10): 3549–3560.